港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

482.357

-14.363-2.89%

漲家數：12

跌家數：18

平家數：3

市盈率：- -

高：497.296

開：496.590

低：481.390

收：496.720

成交量：7,829.28萬

成交額：21.60億

市值：3,067.82億

流通市值：2,726.46億

資料載入中...

總覽新聞資訊

創新藥熱浪來襲，如何把握投資機會？

13億元房租「壓垮」微創系？四公司集體停牌調查

浩歐博(688656.SH)子公司獲得13項醫療器械註冊證

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點

雲頂新耀(01952)首款心血管創新藥星必妥®獲批，首個且唯一成人PSVT應急自救創新療法進入中國

智通财经网

港股收評：港股高開低走恒生科技指數跌1.08％阿里巴巴跌2.18％、騰訊控股跌1.19％

寧夏銀川市市場監管局多措並舉紮實推進新版醫療器械生產質量管理規範落地實施

中国质量新闻网

創新藥概念局部回暖

港股異動 | 和鉑醫藥-B(02142)升逾4% 上半年收入按年增超兩成持續BD驗證公司平台價值

港股異動 | 和鉑醫藥-B(02142.HK)升逾4% 上半年收入按年增超兩成持續BD驗證公司平台價值

港股異動 | 同源康醫藥-B(02410)午後升逾9% EGFR-TKI氘申艾替尼獲批一線治療晚期非小細胞肺癌

百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發

港股異動 | 康諾亞-B(02162)升逾3% 公司國際化戰略迎重要里程碑與Aeira簽署獨家許可協議

港股異動 | 康諾亞-B(02162.HK)升逾3% 公司國際化戰略迎重要里程碑與Aeira簽署獨家許可協議

大行評級丨高盛：下調歌禮制藥目標價至13.86港元，維持「中性」評級

國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉

《大行》里昂：全球製藥供應鏈進入十年重整首選Thermo Fisher(TMO.US)、藥明康德(02359.HK)等平台龍頭

阿斯达克财经

康方依沃西單抗對比K藥III期研究新進展！達到總生存期關鍵次要終點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1574/news?page=16"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":482.35672,"timestamp":1789546124622,"preClose":496.71994,"halted":0,"volume":78292841,"delay":0,"changeRate":-0.028916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-14.36322,"latestTime":"09-16 16:00:00","open":496.59045,"high":497.2955,"low":481.3899,"amount":2159910416.1,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002939,"increases":11,"decrements":18,"flats":3,"marketCap":306781682880,"floatMarketCap":272645614616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":482.35672,"volume":78292841,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002939,"peRate":164.598608,"marketCap":306781682880,"floatMarketCap":272645614616,"timestamp":1789546124622,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":18,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:16,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664987512","title":"創新藥熱浪來襲，如何把握投資機會？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987512","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664987512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:14","pubTimestamp":1788430440,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpzpq4281019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","159992","BK1161","BK1574","MEDX","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875652","title":"13億元房租「壓垮」微創系？四公司集體停牌調查","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875652","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875652?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:07","pubTimestamp":1788430072,"startTime":"0","endTime":"0","summary":"2026年9月1日，因未能按期披露中期业绩，微创医疗及其三家分拆上市的子公司集体停牌。2025年以来微创医疗实施了多项大额资产处置。管理层判断，2026年战略性资产处置收益预计不低于1亿美元。但四家上市公司集体停牌之后，所有子公司的股权处置、二级市场融资全部陷入停滞，原本计划通过减持获取的处置收益无法在停牌状态下落地。这场由一笔巨额租赁引发的集体停牌，将微创医疗推向了“生死闯关”的十字路口。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788430002300175377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02252","BK1583","02172","02160","BK1617","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664987559","title":"浩歐博(688656.SH)子公司獲得13項醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664987559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429879,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)发布公告，公司全资子公司湖南浩欧博生物医药有限公司于近日获得13项由湖南省药品监督管理局核准签发的医疗器械注册证。上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响和促进作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","MDEV","AGNG","BK1583","GDOC","HART","IEIH","MEDX","PTH","BK1100","RSPH","688656","159883","BK0239","LNGR","LGHT","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875311","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875311?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年9月2日获得中国国家药品监督管理局批准磷酸芦可替尼乳膏百卢妥轻中度特应性皮炎的新药上市许可申请，并于2026年九月3日获得药品注册证书。2026年1月，百卢妥中国NDA获批，成为中国批准的首款用于白癜风治疗的外用 JAK抑制剂。继百卢妥获批白癜风适应症后，此次AD适应症NDA获批，将进一步拓展产品的临床应用空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06978","IE00BYV24P56.USD","SG9999015945.SGD","SG9999015986.USD","MEDX","00867","BK1574","IE00BGHQDM52.EUR","SG9999004220.SGD","159992","IBBQ","IE00BVYPNP33.GBP","BK1161","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","SG9999015978.USD","AD","BK1593","BK1191","LNGR","LU2488822045.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664753128","title":"康哲藥業(00867.HK)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664753128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664753128?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","SG9999015978.USD","BK1593","SG9999015986.USD","00867","LU2488822045.USD","SG9999015945.SGD","SG9999004220.SGD","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","SG9999015952.SGD","BK1161","06978","IE00BVYPNQ40.USD","BK1574","IE00BYV24P56.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664731738","title":"一品紅(300723.SZ)：痛風創新藥AR882治療痛風伴高尿酸血癥患者Ⅲ期臨床研究達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664731738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664731738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:47","pubTimestamp":1788428833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红 发布公告，公司全资子公司广州瑞安博医药科技有限公司牵头组织开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅱ/Ⅲ期临床试验，于近日获得顶线分析数据。初步统计结果表明，AR882在痛风伴高尿酸血症参与者中表现出积极的疗效及良好的安全性，试验结果理想，达到预期目的。AR882克服了雷西纳德和苯溴马隆的缺点，能够与尿酸转运蛋白长效结合，延长抑制作用的时间，临床结果显示其药效长达24小时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","300723","BK1574","MEDX","BK1161","LNGR","BK0239","06978","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664189820","title":"雲頂新耀(01952)首款心血管創新藥星必妥®獲批，首個且唯一成人PSVT應急自救創新療法進入中國","url":"https://stock-news.laohu8.com/highlight/detail?id=2664189820","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664189820?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:46","pubTimestamp":1788425209,"startTime":"0","endTime":"0","summary":"9月3日，云顶新耀(01952)宣布，中国国家药品监督管理局(NMPA)已批准星必妥®(艾曲帕米鼻喷雾剂)的新药上市许可申请(NDA)，用于治疗成人阵发性室上性心动过速(PSVT)急性症状发作，转复为窦性心律。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260903/20260903164720_32207.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260903/20260903164720_32207.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","01952","BK1161","BK1583","HRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664272438","title":"港股收評：港股高開低走  恒生科技指數跌1.08％  阿里巴巴跌2.18％、騰訊控股跌1.19％","url":"https://stock-news.laohu8.com/highlight/detail?id=2664272438","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664272438?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:17","pubTimestamp":1788423465,"startTime":"0","endTime":"0","summary":"9月3日，港股高开低走，截至收盘，港股恒生指数跌0.39%，报25213.31点，恒生科技指数跌1.08%，报4468.48点，国企指数跌0.77%，报8385.24点，红筹指数涨0.58%，报4177.46点。大型科技股中，阿里巴巴-W跌2.18%，腾讯控股跌1.19%，京东集团-SW跌1.57%，小米集团-W跌2.21%，网易跌2.03%，美团-W跌1.4%，快手-W跌2.62%，哔哩哔哩-W跌1.64%。腾讯控股：斥资约1亿港元回购22.9万股，回购价435.2-441港元。港股恒生指数和恒生科技指数在7月明显修复后，8月出现调整。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/09/03161758340120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B031HW06.USD","LU2023250504.SGD","LU0708995583.HKD","LU0348784397.USD","LU2279858448.HKD","LU2097828631.EUR","LU1051769294.HKD","NTES","07552","LU1868838027.USD","LU0269904917.USD","LU1961090484.USD","LU0165289439.USD","FFEM","KWEB","SG9999015986.USD","LU0633140727.USD","LU0096374516.USD","IE00B0169L03.USD","LU0029874905.USD","LU0128522744.USD","LU0828237510.HKD","LU0211331839.USD","LU2399975544.HKD","LU0463099449.HKD","HK0000914686.HKD","LU2294711473.HKD","LU0640798160.USD","IE0034224299.USD","LU0326948709.USD","LU0348827113.USD","LU0197773673.USD","03423","LU0049853897.USD","IE00BQXX3D17.EUR","JD","IDRV","LU2097828805.USD","SG9999018865.SGD","LU0823413660.USD","LU0359201612.USD","LU0196878994.USD","BKF","LU0117844026.USD","BK1502","JEMA","LU2237443622.USD","EMCS","IE00B543WZ88.USD","LU1974910355.USD","LU0608807433.USD","LU1675838814.USD","LU0345769631.USD","LU0455707207.USD","SG9999001846.SGD","LU1023057109.AUD","LU0214875030.USD","LU1282651121.HKD","LU0067412154.USD","KSTmain","LU0594300179.USD","LU0456842615.SGD","LU0823039010.USD","LU1226288097.SGD","TCHI","LU2251237488.HKD","LU0210527791.USD","IE00B3M56506.USD","IE00BF5LJ272.USD","LU0107464264.USD","SG9999014674.SGD","SG9999002562.SGD","LU2362541273.HKD","SOCL","LU0784639295.USD","LU0287142896.SGD","IE0032834883.USD","METmain","BK1526","LU0886674414.USD","BK1572","HSHD.SI","LU0878004406.USD","IE00BQXX3F31.USD","LU0823040885.USD","LU0264606111.USD","LU0823426308.USD","FDNI","LU1769817179.HKD","LU1115378108.SGD","03032","LU1251922891.USD","LU1655091459.SGD","IE00BZ08YT58.USD","LU0244354667.USD","BK1607","CXSE","LU3063872942.SGD","LU2152927971.USD","LU1366334578.USD","SG9999007991.SGD","LU1725190679.HKD","LU1201861165.SGD","LU0456846285.SGD","SG9999006514.SGD","LU2237443895.HKD","SG9999001051.SGD","LU0289960550.SGD","LU1733274473.HKD","LU2247934214.USD","LU0348783233.USD","LU0345769128.USD","LU1720050803.USD","LU1044874839.SGD","LU0541502299.USD","LU0588545490.SGD","LU0314109678.HKD","HMTD.SI","AAXJ","LU2133065610.SGD","LU0577902298.EUR","LU0477156797.USD","LU1282648689.USD","LU2148510915.USD","LU2279701549.SGD","LU1224709979.USD","09626","LU0979878070.USD","LU0633140560.USD","LU0011963245.USD","LU0235996351.USD","LU0898667661.SGD","SG9999002463.SGD","LU0231483743.USD","LU1196710351.USD","SG9999001226.SGD","LU1481107354.HKD","HXXD.SI","LU0328353924.USD","BK1608","ODDS","SG9999004220.SGD","LU0589944569.HKD","LU1770034418.SGD","LU0516422366.SGD","XSOE","LU2498475776.HKD","03067","LU1188198961.HKD","LU2087589342.USD","LU0738912210.USD","LU1196710195.USD","LU0143863784.USD","09995","LU0348814723.USD","LI","03692","LU0228659784.USD","LU0348766576.USD","LU0345776255.USD","IE00B97KM107.HKD","LU0593848301.USD","SGXZ90724238.SGD","HSBA.UK","LU0163747925.USD","HK0000286598.CNH","81024","LU1868837722.USD","DRGN","LU0127658192.USD","LU0630378692.HKD","03033","LU2237443382.USD","LU1769817096.USD","03088","LU0052750758.USD","LU2051468812.USD","LU0051755006.USD","LU1733274390.USD","09067","LU0819121731.USD","LU1439103000.SGD","LU0469268626.HKD","LU0642271901.SGD","LU1102505929.USD","GB00BDT5M118.USD","LU1794554557.SGD","89618","03690","LU0417516738.SGD","IE0008368742.USD","IE00B0169N27.USD","IE00B5MMRT66.SGD","LU1688375341.USD","IE0003895053.USD","LU0072913022.USD","LU0737861772.HKD","BK1523","HK0001040143.USD","LU0348767384.USD","LU1504937902.USD","LU2251237306.USD","HK0000352382.USD","LU0588545730.USD","LU1691799644.USD","HK0000151867.HKD","LU1880398471.USD","BK1531","LU0882747503.HKD","LU0918141705.HKD","LU1211504680.USD","03143","LU0320764599.SGD","BK1588","BK1601","LU1810669033.SGD","BK1618","BK1574","LU0070217475.USD","BK1506","LU1981816686.USD","LU0541501648.USD","LU1152091754.HKD","LU1226288170.HKD","LU0611395673.USD","LU0985320562.USD","BK1590","LU1196710864.SGD","BK1589","SG9999017495.SGD","LU0797268264.HKD","LU1808992512.USD","LU0072462343.USD","LU2097828474.EUR","IE00BGV7N243.SGD","LU0106959298.USD","LU0149534421.HKD","LU0856984785.SGD","LU0823397285.USD","BK1591","LU0329678170.USD","SG9999001069.SGD","LU0132412106.USD","LU0531971595.HKD","LU0762540952.USD","LU0164872284.USD","LU0672654166.SGD","IE0008368304.USD","LU0823041008.USD","LU0359202008.SGD","LU0039217434.USD","LU1883866441.USD","LU0531970944.HKD","LU2543165471.USD","LU0873338254.USD","LU1224444064.USD","LU1152091168.USD","BIDD","LU0594300419.USD","LU0320764755.SGD","BK1604","LU1282649067.USD","LU0359201885.HKD","LU0396098781.USD","LU1048596156.SGD","LU0791591158.USD","07226","LU0348735423.USD","LU1105468828.SGD","LU0880133367.SGD","HK0000320264.USD","LU1804176565.USD","SG9999000459.SGD","LU1951186391.HKD","LU0259732245.USD","IE0032431581.USD","LU0608807946.USD","LU1328277881.USD","IE00BMPRXN33.USD","LU0831103253.SGD","LU0588546209.SGD","LU1044875133.USD","HSTECH","LU0315179316.USD","LU0169518387.USD","LU0456827905.SGD","SG9999000327.SGD","SG9999001093.SGD","600276","LU0140636845.USD","00005","SGXZ86797644.SGD","LU0823413587.USD","LU0345775950.USD","LU0431992006.USD","SG9999015945.SGD","BK1610","01810","LU1969619763.USD","LU0414403682.SGD","LU0561508036.HKD","09999","LU2257852520.SGD","SG9999000418.SGD","LU0972618739.USD","LU2106854487.HKD","LU0320764243.SGD","LU2488822045.USD","LU0543330566.HKD","SG9999014914.USD","LU1868837565.USD","BNGE","LU2476274720.SGD","BK1586","LU2462611646.USD","LU2237443978.SGD","LU0828238088.HKD","LU2125910849.SGD","03417","LU0229945570.USD","LU1226287792.SGD","LU1785774172.SGD","LU1048484197.HKD","LU0175139822.USD","SG9999001689.USD","LU0106259558.USD","LU0499858602.USD","LU0130103400.USD","LU1242518857.USD","LU0819123356.HKD","LU0890818403.SGD","IE0008369823.USD","LU0188438112.USD","09088","LU0417516571.SGD","LU0210526637.USD","LU0488056044.USD","LU0862451837.USD","LU1226288253.USD","688331","LU0650527681.SGD","LU0080751232.USD","BK1191","LU0737861699.HKD","SGXZ99366536.SGD","LU0164865239.USD","LU0831093199.SGD","LU0047713382.USD","LU0700851271.USD","EEMX","XIACY","LU0878005551.USD","LU1807302812.USD","LU0106252389.USD","LU1515016050.SGD","LU0675040207.SGD","LU2362540622.SGD","LU0117841782.USD","LU3227948356.SGD","BK1587","09618","09988","LU1226287875.USD","LU1226287529.USD","IE00B8L5B284.USD","BK1233","IE0009570106.USD","LU2476274308.USD","LU1316542783.SGD","LU2008162690.USD","LU0651946864.USD","BK1615","BK1539","SG9999014880.SGD","HK0000320223.HKD","LU0417516902.SGD","LU0828237940.HKD","LU1235295612.USD","LU0329678337.USD","LU0327786744.USD","IE00BPRC5H50.USD","LU2362541513.USD","LU0577902454.USD","SG9999013353.USD","SG9999018857.SGD","LU1960683339.HKD","02565","BK1142","LU2125910500.SGD","LU2778985437.USD","BILI","SG9999014898.SGD","JADE","LU1734074674.USD","LU2242644610.SGD","LU0384037296.USD","LU1102505762.USD","LU0651947912.USD","LU0048597586.USD","LU1303224171.USD","LU0577902611.USD","IE0031814852.USD","SG9999015978.USD","LU0043850808.USD","LU0315178854.USD","LU0203345920.USD","LU1813983027.USD","HK0000352291.HKD","BK1095","LU1328615791.USD","HK0000165453.HKD","HSBC","LU0607220059.USD","LU0164880469.USD","00196","LU0572940350.SGD","LU0449515922.USD","LU0862451753.SGD","LU0823038988.USD","HK0000914660.USD","IE00B067MR52.USD","LU2293587155.HKD","SG9999003461.SGD","LU0149721374.USD","LU2237443549.SGD","SG9999014906.USD","LU0370786039.SGD","SGXZ51526630.SGD","LU1814569148.SGD","LU2097828557.USD","LU0084288322.USD","LU0128522157.USD","BK1119","00700","LU1831875114.USD","BK1521","LU0054237671.USD","LU0605514214.HKD","LU0791590937.USD","LU1629966141.USD","LU0130518102.USD","LU2317271919.USD","BK1619","LU0048388663.USD","BK1193","LU0683595622.HKD","LU1568876335.HKD","SG9999001903.USD","GAMR","BK1163","LU0516422440.USD","BK1202","01024","LU0572939691.SGD","LU1064130708.USD","IE00BMPRXR70.SGD","HBBD.SI","LU2449936058.SGD","LU2045819591.USD","LU0501845795.SGD","LU1568876251.USD","MPNGY","BK1583","IE0003851619.USD","TCEHY","LU0516423091.SGD","LU1770036033.HKD","LU0648000940.SGD","LU1051768304.USD","HK0001040168.HKD","ALBmain","HTCD.SI","LU0348783662.USD","LU0540923850.HKD","89988","LU1008478684.HKD","LU2177674079.SGD","LU0868486357.SGD","02837","LU0211977185.USD","LU0543330483.HKD","BK1231","LU1880383366.USD","IE00B031HY20.USD","SGXZ62798434.SGD","LU1282651048.USD","LU0449509016.USD","LU0630378429.USD","BK1516","02015","LU0762541174.USD","LU1046422090.SGD","LU0197773160.USD","LU0577902538.SGD","LU0254981946.USD","BK1517","LU0577902371.SGD","BK1584","LU1720051017.SGD","LU1366334651.USD","LU0823426480.USD","03310","LU0509642566.USD","LU0648948544.HKD","BK1501","IE0008368411.USD","LU0821914370.USD","LU0143863198.USD","LU0516423174.USD","LU0261947096.USD","LU2357305700.SGD","LU1993786604.SGD","LU0871576103.HKD","LU1956131251.USD","HK0000306685.HKD","IE0003795394.USD","SG9999015952.SGD","IE0001KFT4U8.USD","LU0502904849.HKD","LU2265009873.SGD","LU0029875118.USD","LU2237443465.HKD","LU0228367735.SGD","LU0348723411.USD","LU1880398554.USD","BABA","LU1880383440.USD","LU0173614495.USD","LU1439102457.SGD","SG9999006597.SGD","LU0516422952.EUR","LU0181495838.USD","LU0572944931.SGD","LU2097828714.EUR","LU0865486749.SGD","LU1064131003.USD","LU0307460666.USD","LU2328871848.SGD","LU1642822792.SGD","IE00B29SXG58.USD","IE00BZ08YR35.GBP","SGXZ31699556.SGD","LU1242518931.SGD","IE00BQXX3C00.GBP","LU0210533765.USD","LU0348816934.USD","BK1249","LU0048580855.USD","LU0786609619.USD","LU1720051108.HKD","EMC","IE00BZ08YS42.EUR","LU0251144936.SGD","LU2226246903.HKD","LU2039709279.SGD","ESPO","LU1718418525.SGD","IE00B0JY6N72.USD","LDEM","LU0823397103.USD","HSI","LU0326950275.SGD","LU0261950983.USD","LU0049112450.USD","LU2097829019.USD","LU0348805143.USD","IE00B031J352.USD","LU0634319403.HKD","LU0918141887.USD","LU0588545904.SGD","BK1609","LU1719994722.HKD","LU0348788117.USD","LU1917777945.USD","LU0061477393.USD","LU0762542818.HKD","LU1323998911.USD","LU1548497426.USD","HK0000306701.USD","LU1048588211.SGD","LU1044876610.USD","LU0441854154.USD","81810","01276","BK1161","HK0000107257.USD","LU0499858438.USD","IE00B8HQ1Z84.USD","LU1171460220.USD","SG9999002828.SGD","BK1104","BK1585","LU0348825331.USD","LU0708995153.HKD","LU0192582467.USD","LU1282649141.HKD","SGXZ81514606.USD","LU1282649810.SGD","LU0054450605.USD","LU0293314216.USD","MIUmain","LU0203347892.USD","BK1575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827350","title":"寧夏銀川市市場監管局多措並舉紮實推進新版醫療器械生產質量管理規範落地實施","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827350","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664827350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:48","pubTimestamp":1788421680,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 2025年修订的新版《医疗器械生产质量管理规范》将于2026年11月正式施行。下一步，银川市市场监管局将全面梳理前期新规衔接推进情况及企业预检查问题台账，细化阶段性工作目标和推进举措，持续跟进企业问题整改落实进度，督促企业按期完成整改提升工作，确保新版《医疗器械生产质量管理规范》在该市平稳落地、有序施行，持续规范医疗器械生产秩序，全力守护群众用械安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-03/doc-iniqpvfw2067175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","MDEV","LGHT","PTH","AGNG","RSPH","BK1100","IEIH","MEDX","GDOC","HART","159883","09996","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"創新藥概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664242468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","LNGR","159992","BK1574","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882101","title":"港股異動 | 和鉑醫藥-B(02142)升逾4% 上半年收入按年增超兩成 持續BD驗證公司平台價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882101","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664882101?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:38","pubTimestamp":1788417512,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B涨超4%，截至发稿，涨4.31%，报15.02港元，成交额1.15亿港元。消息面上，近日，和铂医药-B发布截至2026年6月30日止6个月中期业绩，收入1.22亿美元，同比增长20.9%。公告称，于报告期内，收入总额为1.22亿美元，相较于2025年上半年度1.01亿美元增长20.9%。中金研报指出，和铂医药-B上半年业绩超该行预期，主因CTLA-4海外授权增厚收入。持续BD验证公司的平台价值，但合作收入占比仍超过九成，业绩可能随交易及收入确认节奏波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","VXUS","02142","KCAI","BK1583","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664094821","title":"港股異動 | 和鉑醫藥-B(02142.HK)升逾4% 上半年收入按年增超兩成 持續BD驗證公司平台價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2664094821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664094821?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:38","pubTimestamp":1788417512,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824858","title":"港股異動 | 同源康醫藥-B(02410)午後升逾9% EGFR-TKI氘申艾替尼獲批一線治療晚期非小細胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664824858?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:30","pubTimestamp":1788417020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超9%。消息面上，同源康医药近日宣布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已正式获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。同源康预计收取7亿元人民币现金首付款及股份认购款，以及最高20.6亿元人民币的注册里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","09939","BK1574","BK4588","BK1515","VXUS","159938","BK1161","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782740?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01477","BK1161","BK1191","LNGR","BK0216","06978","MEDX","02315","688796","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782159","title":"港股異動 | 康諾亞-B(02162)升逾3% 公司國際化戰略迎重要里程碑 與Aeira簽署獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782159","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782159?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:08","pubTimestamp":1788415700,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B涨超3%，截至发稿，涨2.83%，报79.95港元，成交额7070.11万港元。消息面上，康诺亚-B发布公告，康诺亚与跨国医药公司Aeira Pte. Ltd.签署独家许可协议。根据协议，康诺亚将获得首付款以及不同国家上市申请获批的里程碑付款及商业化里程碑付款，并有权利收取基于许可区域产品净销售额计算高达高双位数率的特许权使用费。康诺亚将持续为Aeira负责司普奇拜单抗注射液的生产和产品供应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1583","VXUS","BK4588","02162","BK1574","BK1161","BK4585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664592821","title":"港股異動 | 康諾亞-B(02162.HK)升逾3% 公司國際化戰略迎重要里程碑 與Aeira簽署獨家許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664592821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664592821?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:08","pubTimestamp":1788415700,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","BK1587","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664014829","title":"大行評級丨高盛：下調歌禮制藥目標價至13.86港元，維持「中性」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664014829","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664014829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:04","pubTimestamp":1788415446,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01672","BK1191","BK1161","01477","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","159992","MEDX","BK1574","LNGR","BK1161","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826093","title":"《大行》里昂：全球製藥供應鏈進入十年重整  首選Thermo Fisher(TMO.US)、藥明康德(02359.HK)等平台龍頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826093","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826093?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 13:15","pubTimestamp":1788412500,"startTime":"0","endTime":"0","summary":"里昂发表全球医疗健康行业展望报告指出，全球制药供应链正进入长达十年的重整。价值创造将愈来愈集中于具备规模、技术，以及全球在地布局的平台型龙头，该行认为Thermo Fisher、瑞士Lonza及中国药明康德分别体现美国、欧洲及中国的结构优势，为本轮行业重置的首选受惠者。个股方面，该行首次覆盖Thermo Fisher予“跑赢大市”评级，目标价748美元，看好其作为领先生命科学工具平台，对生物制药投资复苏及美国制造回流具最广曝光。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419153917927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542763/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542763/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","LU1997244956.HKD","LU1934453819.USD","LU0348767384.USD","LU1303224171.USD","IE00BPRC5H50.USD","LU1046422090.SGD","LU2242644610.SGD","LU0348766576.USD","LU1251922891.USD","BK1576","BK1191","LU0611395673.USD","IE00B5MMRT66.SGD","LU2495084118.USD","LU1770034418.SGD","BK0216","LU0456842615.SGD","LU1808992512.USD","LU1997245177.USD","BK1574","LU0469268626.HKD","BK1141","LU0700851271.USD","LU0320764599.SGD","01477","LU1997245094.SGD","LU1979443071.USD","LU1969619763.USD","LU2125910500.SGD","LU2488822045.USD","LU0572944931.SGD","LU2045819591.USD","LU2328871848.SGD","603259","LU1719994722.HKD","LU0052750758.USD","IE00B543WZ88.USD","LU0327786744.USD","02359","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826458","title":"康方依沃西單抗對比K藥III期研究新進展！達到總生存期關鍵次要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826458","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826458?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 12:49","pubTimestamp":1788410980,"startTime":"0","endTime":"0","summary":"9月3日，康方生物（9926.HK）宣布，依沃西单抗（商品名：依达方?）对比帕博利珠单抗（K药）一线治疗PD-L1表达阳性（PD-L1TPS≥1%）的局部晚期或转移性非小细胞肺癌（NSCLC）的III期临床研究（HARMONi-2/AK112-303），在期中分析中达到了总生存期（OS）关键次要终点，取得具有统计学显著性和临床获益的阳性结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033863892417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033863892417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348783233.USD","IE00B543WZ88.USD","LU1961090484.USD","LU2476274308.USD","BK1161","LU0348766576.USD","LU0348735423.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","09926","LU1794554557.SGD","LU0348767384.USD","LU0417516902.SGD","LU2399975544.HKD","LU1720050803.USD","LU2476274720.SGD","LU2488822045.USD","LU0348784397.USD","KURE","LU0348827113.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348825331.USD","LU0634319403.HKD","LU0417516738.SGD","BK1574","LU0561508036.HKD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":16,"totalSize":329,"code":"91000000","status":"200"}]}}